29 Mar 2023 Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
29 Mar 2023 Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
28 Mar 2023 Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone
28 Mar 2023 OncoVerity, Inc. Announces Exclusive Worldwide Licensing Rights to Cusatuzumab and Appoints Max Colao as Chief Executive Officer
28 Mar 2023 KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status
27 Mar 2023 Agenus’ Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian Cancer
27 Mar 2023 Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)
25 Mar 2023 Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
25 Mar 2023 ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates
23 Mar 2023 BLA Accepted in China for Boan Biotech's Denosumab Injection (BA1102) for the Oncology Indications
23 Mar 2023 Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
23 Mar 2023 FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
23 Mar 2023 Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
23 Mar 2023 Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
22 Mar 2023 Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody
22 Mar 2023 Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series
22 Mar 2023 Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
21 Mar 2023 BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
21 Mar 2023 Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
21 Mar 2023 Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas
20 Mar 2023 Samsung Bioepis Presents Phase 1 Study Results of SB17 (Ustekinumab), A Proposed Biosimilar to Stelara, at 2023 AAD Annual Meeting
19 Mar 2023 LEO Pharma Presents Late-Breaking Positive Phase 2a Efficacy and Safety Results of LEO 138559 in Moderate-to-Severe Atopic Dermatitis at the 2023 AAD Annual Meeting
17 Mar 2023 Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database
17 Mar 2023 Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously
16 Mar 2023 Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up